{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:17:04Z","timestamp":1737695824642,"version":"3.33.0"},"reference-count":22,"publisher":"Walter de Gruyter GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2024-0520_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Because patients with type 1 diabetes mellitus (T1DM) have persistent and profound limitations in immune functions, immune response to vaccines may diminish. The aim of our study was to compare the antibody to Hepatitis B surface antigen (anti-HBs) serologies of children with T1DM, at the time of T1DM diagnosis, who were vaccinated according to the vaccination schedule with the anti-HBs serologies of healthy children. And to investigate the relationship between anti-HBs levels and the accompanying variables of these patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2024-0520_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Anti-HBs and Hepatitis B surface antigen (HBs Ag) results of 214 children with T1DM and 210 healthy children were recorded retrospectively. Seropositivity rates for anti-HBs were compared between T1DM and control groups and the odds of seropositivity were examined. Clinical and\u00a0laboratory data of T1DM patients were investigated according to anti-HBs seropositivity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2024-0520_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Anti-HBs seropositivity rates and titers in the T1DM group were significantly lower than those in the healthy group. According to anti-HBs status among T1DM patients; no difference was found in terms of gender, BMI, presence of comorbidities, presence of autoantibodies and lipid profiles. Diagnosis age and HbA1c levels of anti-HBs negative group were higher than anti-HBs positive group in patients diagnosed with T1DM. However, neither age nor HbA1c level was found to significantly change the odds of the seropositivity for anti-HBs in T1DM patients after adjustment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2024-0520_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We recommend that children diagnosed with T1DM should have anti-HBs serology tested at the time of diagnosis and seronegative patients should have additional hepatitis B vaccination.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2024-0520","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:11:56Z","timestamp":1737630716000},"source":"Crossref","is-referenced-by-count":0,"title":["Do children with type 1 diabetes mellitus remain protected against hepatitis B?"],"prefix":"10.1515","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1712","authenticated-orcid":false,"given":"P\u0131nar","family":"Y\u0131lmazba\u015f","sequence":"first","affiliation":[{"name":"Department of Pediatrics , Health Science University, Prof Dr Cemil Ta\u015fc\u0131o\u011flu City Hospital , Istanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3977-5527","authenticated-orcid":false,"given":"Di\u011fdem","family":"Bezen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology , Health Science University, Prof Dr Cemil Ta\u015fc\u0131o\u011flu City Hospital , Istanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-1123","authenticated-orcid":false,"given":"Eren","family":"Vurgun","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry , Health Science University, Prof Dr Cemil Ta\u015fc\u0131o\u011flu City Hospital , Istanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"2025012311114972735_j_jpem-2024-0520_ref_001","unstructured":"Mast, EE, Weinbaum, CM, Fiore, AE, Alter, MJ, Bell, BP, Finelli, L, et al.. Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55:1\u201333."},{"key":"2025012311114972735_j_jpem-2024-0520_ref_002","unstructured":"Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report (MMWR). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep 2011;60:1709\u201312."},{"key":"2025012311114972735_j_jpem-2024-0520_ref_003","doi-asserted-by":"crossref","unstructured":"Tahir, A, Shinkafi, SH, Alshrari, AS, Yunusa, A, Umar, MT, Hudu, SA, et al.. A comprehensive review of hepatitis B vaccine nonresponse and associated risk factors. Vaccines 2024;12:710. https:\/\/doi.org\/10.3390\/vaccines12070710.","DOI":"10.3390\/vaccines12070710"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_004","doi-asserted-by":"crossref","unstructured":"Berbudi, A, Rahmadika, N, Tjahjadi, AI, Ruslami, R. Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev 2020;16:442\u20139. https:\/\/doi.org\/10.2174\/1573399815666191024085838.","DOI":"10.2174\/1573399815666191024085838"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_005","doi-asserted-by":"crossref","unstructured":"Esposito, S, Mariotti Zani, E, Torelli, L, Scavone, S, Petraroli, M, Patianna, V, et al.. Childhood vaccinations and type 1 diabetes. Front Immunol 2021;12:667889. https:\/\/doi.org\/10.3389\/fimmu.2021.667889.","DOI":"10.3389\/fimmu.2021.667889"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_006","doi-asserted-by":"crossref","unstructured":"Schillie, SF, Spradling, PR, Murphy, TV. Immune response of hepatitis B vaccine among persons with diabetes: a systematic review of the literature. Diabetes Care 2012;35:2690\u20137. https:\/\/doi.org\/10.2337\/dc12-0312.","DOI":"10.2337\/dc12-0312"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_007","unstructured":"Centers for Disease Control and Prevention. Table\u00a03 recommended child and adolescent immunization schedule by medical indication, United States; 2020. Available from: https:\/\/www.cdc.gov\/vaccines\/schedules\/hep\/imz\/child-indications."},{"key":"2025012311114972735_j_jpem-2024-0520_ref_008","doi-asserted-by":"crossref","unstructured":"Reilly, ML, Schillie, SF, Smith, E, Poissant, T, Vonderwahl, CW, Gerard, K, et al.. Increased risk of acute hepatitis B among adults with diagnosed diabetes mellitus. J Diabetes Sci Technol 2012;6:858\u201366. https:\/\/doi.org\/10.1177\/193229681200600417.","DOI":"10.1177\/193229681200600417"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_009","doi-asserted-by":"crossref","unstructured":"Ocak, S, Eskiocak, AF. The evaluation of immune responses to hepatitis B vaccination in diabetic and non-diabetic haemodialysis patients and the use of tetanus toxoid. Nephrology 2008;13:487\u201391. https:\/\/doi.org\/10.1111\/j.1440-1797.2008.00936.x.","DOI":"10.1111\/j.1440-1797.2008.00936.x"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_010","doi-asserted-by":"crossref","unstructured":"Fi\u00e7icio\u011flu, C, Mikla, S, Midilli, K, Aydin, A, Cam, H, Er\u011fin, S. Reduced immune response to hepatitis B vaccine in children with insulin dependent diabetes. Acta Paediatr Jpn 1995;37:687\u201390. https:\/\/doi.org\/10.1111\/j.1442-200x.1995.tb03404.x.","DOI":"10.1111\/j.1442-200X.1995.tb03404.x"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_011","doi-asserted-by":"crossref","unstructured":"Chang, VMM, Karnchanasorn, R, Ou, HY, Samoa, R, Chuang, LM, Chiu, KC. The impact of glucose tolerance state on seropositivity rate after hepatitis B vaccination. Sci Rep 2022;12:3087. https:\/\/doi.org\/10.1038\/s41598-022-07163-x.","DOI":"10.1038\/s41598-022-07163-x"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_012","doi-asserted-by":"crossref","unstructured":"Leonardi, S, Vitaliti, G, Garozzo, MT, Miraglia del Giudice, M, Marseglia, G, La Rosa, M. Hepatitis B vaccination failure in children with diabetes mellitus? The debate continues. Hum Vaccin Immunother 2012;8:448\u201352. https:\/\/doi.org\/10.4161\/hv.19107.","DOI":"10.4161\/hv.19107"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_013","doi-asserted-by":"crossref","unstructured":"Jack, AD, Hall, AJ, Maine, N, Mendy, M, Whittle, HC. What level of hepatitis B antibody is protective? J Infect Dis 1999;179:489\u201392. https:\/\/doi.org\/10.1086\/314578.","DOI":"10.1086\/314578"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_014","doi-asserted-by":"crossref","unstructured":"Demir, K, \u00d6zen, S, Konak\u00e7\u0131, E, Ayd\u0131n, M, Darendeliler, F. A comprehensive online calculator for pediatric endocrinologists: \u00c7EDD \u00c7\u00f6z\u00fcm\/TPEDS Metrics. J Clin Res Pediatr Endocrinol 2017;9:182\u20134. https:\/\/doi.org\/10.4274\/jcrpe.4526.","DOI":"10.4274\/jcrpe.4526"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_015","doi-asserted-by":"crossref","unstructured":"Elrashidy, H, Elbahrawy, A, El-Didamony, G, Mostafa, M, George, NM, Elwassief, A, et al.. Antibody levels against hepatitis B virus after hepatitis B vaccination in Egyptian diabetic children and adolescents. Hum Vaccin Immunother 2013;9:2002\u20136. https:\/\/doi.org\/10.4161\/hv.25426.","DOI":"10.4161\/hv.25426"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_016","doi-asserted-by":"crossref","unstructured":"Min, E, Min, J, Kim, R. Age-specific seroprotection after Hepatitis\u00a0B\u00a0virus vaccination among Korean American pediatric population in\u00a0Queens, New York. Hum Vaccin Immunother 2022;18:2053404. https:\/\/doi.org\/10.1080\/21645515.2022.2053404.","DOI":"10.1080\/21645515.2022.2053404"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_017","doi-asserted-by":"crossref","unstructured":"Vesikari, T, Langley, JM, Segall, N, Ward, BJ, Cooper, C, Poliquin, G, et al.. PROTECT Study Group. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. Lancet Infect Dis 2021;21:1271\u201381. https:\/\/doi.org\/10.1016\/S1473-3099(20)30780-5.","DOI":"10.1016\/S1473-3099(20)30780-5"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_018","doi-asserted-by":"crossref","unstructured":"Pinhas-Hamiel, O, Hamiel, U, Boyko, V, Graph-Barel, C, Reichman, B, Lerner-Geva, L. Trajectories of HbA1c levels in children and youth with type 1 diabetes. PLoS ONE 2014;9:e109109. https:\/\/doi.org\/10.1371\/journal.pone.0109109.","DOI":"10.1371\/journal.pone.0109109"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_019","doi-asserted-by":"crossref","unstructured":"Hartal, M, Yavnai, N, Galor, I, Avramovich, E, Sela, T, Kayouf, R, et al.. Seroprevalence of anti-HBs antibodies at young adulthood, before and after a booster vaccine dose, among medical personnel vaccinated in infancy. Vaccine 2015;33:4878\u201385. https:\/\/doi.org\/10.1016\/j.vaccine.2015.07.058.","DOI":"10.1016\/j.vaccine.2015.07.058"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_020","doi-asserted-by":"crossref","unstructured":"Zhao, H, Zhou, YH. Revaccination against hepatitis B in late teenagers who received vaccination during infancy: yes or no? Hum Vaccin Immunother 2018;14:456\u201363. https:\/\/doi.org\/10.1080\/21645515.2017.1397243.","DOI":"10.1080\/21645515.2017.1397243"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_021","doi-asserted-by":"crossref","unstructured":"Schillie, S, Harris, A, Link-Gelles, R, Romero, J, Ward, J, Nelson, N. Recommendations of the advisory committee on immunization practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep 2018;67:455\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm6715a5.","DOI":"10.15585\/mmwr.mm6715a5"},{"key":"2025012311114972735_j_jpem-2024-0520_ref_022","doi-asserted-by":"crossref","unstructured":"Silvestri, F, Tromba, V, Mazzotta, I, Costantino, F. How does diabetes type 1 affects immune response to hepatitis B virus vaccine in pediatric population? Evaluation of a booster dose in unresponsive subjects with type 1 diabetes. Minerva Pediatr 2023;75:822\u20137. https:\/\/doi.org\/10.23736\/S2724-5276.19.05678-0.","DOI":"10.23736\/S2724-5276.19.05678-0"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0520\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0520\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:12:09Z","timestamp":1737630729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0520\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":22,"alternative-id":["10.1515\/jpem-2024-0520"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2024-0520","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]}}}